72275-67-3

Usage

Uses

Used in Pharmaceutical Industry:
Astromicin sulfate is used as an antibiotic agent for the treatment of various bacterial infections. Its broad-spectrum activity makes it effective against a variety of bacteria, including those that have developed resistance to other commonly used aminoglycoside antibiotics. This property allows it to be a valuable option in treating infections caused by resistant strains.
Used in Hospital Settings:
In hospitals and other healthcare facilities, Astromicin sulfate is used as a therapeutic agent for managing severe bacterial infections, particularly when other antibiotics have proven to be ineffective. Its ability to target resistant bacteria makes it a crucial component in the treatment arsenal against drug-resistant infections.
Used in Research and Development:
Astromicin sulfate is also utilized in research settings to study the mechanisms of antibiotic resistance and to develop new strategies for combating resistant bacteria. Understanding its mode of action and resistance profile can aid in the design of novel antibiotics and treatment approaches.

Therapeutic Function

Antibiotic

InChI:InChI=1/C17H35N5O6.2H2O4S/c1-7(19)9-5-4-8(20)17(27-9)28-15-11(21)13(24)16(26-3)12(14(15)25)22(2)10(23)6-18;2*1-5(2,3)4/h7-9,11-17,24-25H,4-6,18-21H2,1-3H3;2*(H2,1,2,3,4)/t7-,8+,9-,11-,12-,13-,14+,15+,16+,17+;;/m0../s1

Upstream product

• 67010-18-8 6'-epi-fortimicin A 
• 66962-55-8 1,2',6'-tri-N-benzyloxycarbonyl-6'-epi-fortimicin B 
• 66962-56-9 1,2',6',2-tetra-N-benzyloxycarbonyl-6'-epi-fortimicin B 
• 67010-18-8 2-epi-fortimicin A tetrahydrochloride 
• 66962-55-8 1,2',6'-tri-N-benzyloxycarbonyl-2-epi-fortimicin B 
• 66962-56-9 1,2',6',2''-tetra-N-benzyloxycarbonyl-2-epi-fortimicin A 
• 76801-55-3 1,2',6'-tri-N-acetyl-2-epi-fortimicin B 4,5-carbamate 
• 76801-59-7 2-O-benzyl-1,2',6'-tri-N-benzyloxycarbonyl-2-epi-fortimicin B 
• 76801-58-6 2-O-benzyl-2-epi-fortimicin B 
• 79198-79-1 ((3R,5S,6R)-4-Benzyloxycarbonylamino-3-{(2R,3R)-3-benzyloxycarbonylamino-6-[(S)-1-(2,2,2-trichloro-ethoxycarbonylamino)-ethyl]-tetrahydro-pyran-2-yloxy}-2,5-dihydroxy-6-methoxy-cyclohexyl)-methyl-carbamic acid 2,2,2-trichloro-ethyl ester 
• 78740-86-0 1,2'-di-N-benzyloxycarbonyl-6'-N-(2,2,2-trichloroethoxycarbonyl)-fortimicin B-4,5-carbamate 
• 79198-78-0 1,2'-di-N-benzyloxycarbonyl-6'-N-chlorofortimicin B-4,5-carbamate 
• 78740-88-2 1,2'-di-N-benzyloxycarbonyl-6'-iminofortimicin B-4,5-carbamate 
• 54783-95-8 2-epi-fortimicin B 

Downstream Products

• 72351-18-9 1,4-bis-N-(benzyloxycarbonyl)fortamine B 
• 54783-95-8 fortimicin B 
• 71241-90-2 2'-N-glycylfortimicin B 

Relevant academic research and scientific papers

PREPARATIONS OF 2-epi-FORTIMICINS A FROM 2-epi-FORTIMICIN B BY INTRAMOLECULAR BASE-CATALYZED 2-O-ACYLATION OF 1,2',6'-TRI-N-BENZYLOXYCARBONYL-2-EPI-FORTIMICIN B

Preparation of 2-epi-fortimicin A (4) from 2-epi-fortimicin B (3) are described.In contrast to the previously reported, selective 4-N-acylation of 1,2',6'-tri-N-benzyloxycarbonylfortimicin B (8) with N-(N-benzyloxycarbonylglycyloxy)succinimide, 1,2',6'-tr

Fortimicin B derivatives and process for production thereof

The present invention relates to certain novel 4-N-substituted derivatives of the antibiotic Fortimicin B and processes for production thereof. Included in the process aspect of the invention, is a novel method for the semi-synthetic production of the antibiotic Fortimicin C.